Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
NCT07425392Phase 3Active, not recruiting
- Sponsor
- Vaxcyte
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VAX-31 in pneumococcal disease, sponsored by Vaxcyte. Started Feb 2026; status: active, not recruiting.
02
Drugs
VAX-31
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07425392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425392.